NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Forecast, Price & News

$50.42

+12.95 (+34.56%)

(As of 09/29/2023 ET)

Compare

Today's Range: $48.55
▼
$65.51
50-Day Range: $26.49
▼
$50.42
52-Week Range: $20.80
▼
$65.51

Volume: 9.97 million shs
Average Volume: 545,955 shs
Market Capitalization: $1.93 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $59.50

Structure Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 18.0% Upside
$59.50 Price Target
Short Interest: Bearish
6.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.60
Based on 20 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.88) to ($0.92) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.37 out of 5 stars

Medical Sector

930th out of 971 stocks

Pharmaceutical Preparations Industry

427th out of 445 stocks

2.5

Analyst's Opinion

Consensus Rating
Structure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $59.50, Structure Therapeutics has a forecasted upside of 18.0% from its current price of $50.42.
Amount of Analyst Coverage
Structure Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.58% of the float of Structure Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Structure Therapeutics has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Structure Therapeutics has recently decreased by 4.98%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Structure Therapeutics does not currently pay a dividend.
Dividend Growth
Structure Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GPCR.

2.0

News and Social Media Coverage

News Sentiment
Structure Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for Structure Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Structure Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
46.12% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Structure Therapeutics are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.

See Top Rated MarketRank™ Stocks Here

About Structure Therapeutics (NASDAQ:GPCR) Stock

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Price History

30 days | 90 days | 365 days | Advanced Chart

GPCR Stock News Headlines

October 1, 2023 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) PT Raised to $79.00 at Jefferies Financial Group

October 1, 2023 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) PT Raised to $97.00

October 1, 2023 | Behind the Markets (Ad)

U.S. Loses to China in Shocking WAR GAMES

=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

October 1, 2023 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week High on Analyst Upgrade

September 30, 2023 | msn.com

Structure Therapeutics surges as early data from obesity pill tops expectations

September 30, 2023 | msn.com

Structure Therapeutics surges after early-stage data for oral weight loss agent

September 30, 2023 | msn.com

GLP-1 drug developer Carmot Therapeutics reportedly mulling IPO or buyout

September 29, 2023 | msn.com

Leerink sees Structure Therapeutics stock as "undervalued"

October 1, 2023 | Behind the Markets (Ad)

U.S. Loses to China in Shocking WAR GAMES

September 29, 2023 | finance.yahoo.com

Structure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity Treatment

September 29, 2023 | finanznachrichten.de

Structure Therapeutics Inc.: Structure Therapeutics Announces $300 Million Private Placement Equity Financing

September 29, 2023 | msn.com

Structure's Obesity Pill Could Challenge Lilly, Novo, Small Study Suggests

September 29, 2023 | reuters.com

Structure Therapeutics surges on promising early stage obesity drug data

September 29, 2023 | finance.yahoo.com

Why Shares of Structure Therapeutics Are Soaring on Friday

September 29, 2023 | tmcnet.com

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

September 29, 2023 | benzinga.com

Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?

September 29, 2023 | msn.com

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

September 29, 2023 | markets.businessinsider.com

Structure Therapeutics Sets $300 Mln Private Placement Equity Financing

August 31, 2023 | businesswire.com

Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies

August 28, 2023 | seekingalpha.com

Structure Therapeutics: Recent IPO With Large Valuation

August 11, 2023 | msn.com

Structure Therapeutics GAAP EPS of -$0.20

August 11, 2023 | markets.businessinsider.com

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

August 11, 2023 | finance.yahoo.com

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

August 3, 2023 | finance.yahoo.com

Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors

August 2, 2023 | thestreet.com

Qualcomm Unveils New Corporate Structure

July 28, 2023 | cnbc.com

This under-the-radar biotech could be the next way to play the obesity drug boom

July 17, 2023 | finance.yahoo.com

Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets

See More Headlines

Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GPCR Company Calendar

Last Earnings: 8/10/2023
Today: 10/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GPCR
CUSIP: N/A
CIK: 1888886
Web: www.structuretx.com
Phone: 628-229-9277
Fax: N/A
Employees: 77
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $59.50
High Stock Price Forecast: $97.00
Low Stock Price Forecast: $33.00
Forecasted Upside/Downside: +18.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.20
Quick Ratio: 15.20

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 38,270,000
Free Float: N/A
Market Cap: $1.93 billion
Optionable: Not Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Raymond C. Stevens Ph.D. (Age 59)
CEO & Director
Comp: $747.33k

Dr. Yingli Ma Ph.D. (Age 49)
Chief Technology Officer
Comp: $497.58k

Dr. Mark A. Bach M.D. (Age 66)
Ph.D., Chief Medical Officer
Comp: $628.37k

Mr. Jun S. Yoon (Age 45)
Co- Founder, CFO & Sec.

Dr. Xichen Lin Ph.D. (Age 49)
Chief Scientific Officer

Mr. Tony Peng
Sr. VP of Legal

Dr. Hui Lei Ph.D.
Sr. VP of Chemistry

Ms. Melita Sun Jung (Age 46)
Chief Bus. Officer

Dr. Fang Zhang Ph.D.
Exec. VP & Head of Biology

Ms. Lani Ibarra
Sr. VP of Clinical Devel. Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GPCR Stock - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings or view top-rated stocks.
What is Structure Therapeutics' stock price forecast for 2023?: 6 brokers have issued 1 year target prices for Structure Therapeutics' shares. Their GPCR share price forecasts range from $33.00 to $97.00. On average, they anticipate the company's stock price to reach $59.50 in the next twelve months. This suggests a possible upside of 18.0% from the stock's current price.
View analysts price targets for GPCR or view top-rated stocks among Wall Street analysts.
How have GPCR shares performed in 2023?: Structure Therapeutics' stock was trading at $26.00 on January 1st, 2023. Since then, GPCR shares have increased by 93.9% and is now trading at $50.42.
View the best growth stocks for 2023 here.
How were Structure Therapeutics' earnings last quarter?: Structure Therapeutics Inc. (NASDAQ:GPCR) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01.
What ETF holds Structure Therapeutics' stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 3,513 shares of GPCR stock, representing 0.96% of its portfolio.
When did Structure Therapeutics IPO?: (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share.

What is Structure Therapeutics' stock symbol?: Structure Therapeutics trades on the NASDAQ under the ticker symbol "GPCR."
When did the company's lock-up period expire?: Structure Therapeutics' lock-up period expired on Wednesday, August 2nd. Structure Therapeutics had issued 10,740,000 shares in its initial public offering on February 3rd. The total size of the offering was $161,100,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.
How do I buy shares of Structure Therapeutics?: Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Structure Therapeutics' stock price today?: One share of GPCR stock can currently be purchased for approximately $50.42.
How much money does Structure Therapeutics make?: Structure Therapeutics (NASDAQ:GPCR) has a market capitalization of $1.93 billion.
How can I contact Structure Therapeutics?: The official website for the company is www.structuretx.com. The company can be reached via phone at 628-229-9277 or via email at ir@structuretx.com.

This page (NASDAQ:GPCR) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Structure Therapeutics (GPCR) Stock Forecast, Price & News

Structure Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Structure Therapeutics (NASDAQ:GPCR) Stock

GPCR Price History

GPCR Stock News Headlines

GPCR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

GPCR Stock - Frequently Asked Questions

Overall MarketRank^™